THE MAIN REASONS WHY CANCER IS SO DIFFICULT TO TREATMENT

PDF

Published: 2020-10-29

Page: 50-52


ALI ADEL DAWOOD *

College of Medicine, University of Mosul, Mosul, Iraq.

WALEED ISMAEEL YOUSIF

College of Medicine, University of Nineveh, Mosul, Iraq.

*Author to whom correspondence should be addressed.


Abstract

The “Type of Article” of this paper is “Letter to the Editor”. This paper discuses about: “THE MAIN REASONS WHY CANCER IS SO DIFFICULT TO TREATMENT”. No formal abstract is available. Readers are requested to read the full article.


How to Cite

DAWOOD, A. A., & YOUSIF, W. I. (2020). THE MAIN REASONS WHY CANCER IS SO DIFFICULT TO TREATMENT. Asian Journal of Advances in Medical Science, 2(1), 50–52. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/1693

Downloads

Download data is not yet available.

References

Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–837.

Copland M, Jorgensen HG, Holyoake TL. Evolving molecular therapy for chronic myeloid leukaemia-are we on target? Hematology. 2005;10:349–359.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.

Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol; 2013 [PubMed].

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–1570.

Abrams J, Conley B, Mooney M. National cancer institute's precision medicine initiatives for the new national clinical trials network. Am. Soc. Clin. Oncol. Educ. Book. 2014;71–76. [PubMed].

Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer. 2014;14:623–631.

Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472–12508.

Catenacci DVT. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967–996.

FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab), Merk; 2020. Available:https://www.merck.com/?s=Keytruda.

Bang YJ, Van Cutsem E. Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.